Repository logo
 
Publication

Liraglutide effectiveness in type 2 diabetes: insights from a real-world cohort of Portuguese patients

2022-11Journal article Open access
Simple item page
dc.contributor.authorSilva-Nunes, José
dc.contributor.authorNascimento, Edite
dc.contributor.authorLouro, Joana
dc.contributor.authorDores, Jorge
dc.contributor.authorLaginha, Teresa
dc.contributor.authorGonçalves-Ferreira, Ana
dc.contributor.authorAlves, Marta
dc.contributor.authorSouto, Selma B.
dc.contributor.authorCunha, Nelson
dc.contributor.authorPina, Elsa
dc.contributor.authorDuarte, Rui
dc.contributor.authorRaposo, João Filipe
dc.date.accessioned2022-12-07T15:12:13Z
dc.date.available2022-12-07T15:12:13Z
dc.date.issued2022-11
dc.description.abstractLiraglutide is a long-acting glucagon-like peptide-1 receptor agonist prescribed to diabetic patients for glycaemic control. To understand the impact of liraglutide in the real-world setting, this study analysed its effects in a Portuguese cohort of Type 2 diabetes patients. This was an observational, multicentric, and retrospective study that included 191 liraglutide-treated patients with at least 12 months of treatment. Patients' data were collected and analysed during a 24-month follow-up period. Overall, liraglutide treatment effectively reduced HbA1c levels from 8.3% to around 7.5%, after 6, 12, and 24 months (p < 0.001). In fact, 38.2%, 37.2%, and 44.8% of patients at 6, 12, and 24 months, respectively, experienced an HbA1c reduction of at least 1%. Moreover, a persistent reduction in anthropometric features was also observed, with 44.0%, 47.6%, and 54.4% of patients achieving a weight reduction of at least 3% at 6, 12, and 24 months, respectively. Finally, significant improvements were observed in the HDL-c and LDL-c levels. Our results demonstrate that liraglutide effectively promoted the reduction of HbA1c values during routine clinical practice, which was sustained throughout the study. In addition, there were significant improvements in anthropometric parameters and other cardiovascular risk factors.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSilva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Gonçalves-Ferreira A, et al. Liraglutide effectiveness in type 2 diabetes: insights from a real-world cohort of Portuguese patients. Metabolites. 2022;12(11):1121.pt_PT
dc.identifier.doi10.3390/metabo12111121pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/15127
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relation.publisherversionhttps://www.mdpi.com/2218-1989/12/11/1121pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectAnthropometric parameterspt_PT
dc.subjectCardiovascular risk factorspt_PT
dc.subjectGlycemic controlpt_PT
dc.subjectLiraglutidept_PT
dc.subjectReal-world evidencept_PT
dc.subjectDiabetes type 2pt_PT
dc.titleLiraglutide effectiveness in type 2 diabetes: insights from a real-world cohort of Portuguese patientspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue11pt_PT
oaire.citation.startPage1121pt_PT
oaire.citation.titleMetabolitespt_PT
oaire.citation.volume12pt_PT
person.familyNameSilva-Nunes
person.givenNameJosé António
person.identifier.ciencia-id4B1C-E132-25F0
person.identifier.orcid0000-0002-4728-1220
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication9352b380-9661-4316-ab88-6ed9be1020ac
relation.isAuthorOfPublication.latestForDiscovery9352b380-9661-4316-ab88-6ed9be1020ac

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Liraglutide effectiveness in type 2 diabetes_insights from a real-world cohort of Portuguese patients.pdf
Size:
423.49 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos